<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><meta name="description" content='The DST01_3 Disposition Table provides an overview of patients study treatment status. For patients who discontinued
the study, the reason provided is categorized as "Safety" or "Non-Safety" issue.'><title>DST01 Table 3 (Supplementary) Patient Disposition Table 3. — dst01_3_main • chevron</title><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.2.2/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.2.2/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="DST01 Table 3 (Supplementary) Patient Disposition Table 3. — dst01_3_main"><meta property="og:description" content='The DST01_3 Disposition Table provides an overview of patients study treatment status. For patients who discontinued
the study, the reason provided is categorized as "Safety" or "Non-Safety" issue.'><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--><link rel="stylesheet" href="../consent.css"><script src="../consent.js" type="text/javascript" charset="utf-8"></script></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">chevron</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.1.1.9040</small>

    <div style="width: 140px; margin-left: 0.5rem;"> <small class="nav-text text-muted me-auto">part of</small> <img src="https://github.com/insightsengineering/hex-stickers/blob/main/PNG/nest.png?raw=true" alt="NEST" style="height: 30px;"><a href="https://pharmaverse.org/" class="external-link"><img src="https://github.com/insightsengineering/hex-stickers/blob/main/PNG/pharmaverse.png?raw=true" alt="pharmaverse" style="height: 28px;"></a> </div>
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="nav-item">
  <a class="nav-link" href="../articles/chevron.html">Get started</a>
</li>
<li class="active nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="nav-item">
  <a class="nav-link" href="../articles/index.html">Articles</a>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul><form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off"></form>

      <ul class="navbar-nav"><li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/insightsengineering/chevron">
    <span class="fa fa-github"></span>
     
  </a>
</li>
      </ul></div>

    
  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>DST01 Table 3 (Supplementary) Patient Disposition Table 3.</h1>
      
      <div class="d-none name"><code>dst01_3.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>The DST01_3 Disposition Table provides an overview of patients study treatment status. For patients who discontinued
the study, the reason provided is categorized as "Safety" or "Non-Safety" issue.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">dst01_3_main</span><span class="op">(</span></span>
<span>  <span class="va">adam_db</span>,</span>
<span>  arm_var <span class="op">=</span> <span class="st">"ARM"</span>,</span>
<span>  status_var <span class="op">=</span> <span class="st">"EOSSTT"</span>,</span>
<span>  disc_reason_var <span class="op">=</span> <span class="st">"DCSREAS"</span>,</span>
<span>  status_treatment_var <span class="op">=</span> <span class="st">"EOTSTT"</span>,</span>
<span>  lbl_overall <span class="op">=</span> <span class="st">"All Patients"</span>,</span>
<span>  deco <span class="op">=</span> <span class="fu"><a href="std_deco.html">std_deco</a></span><span class="op">(</span><span class="st">"DST01"</span><span class="op">)</span>,</span>
<span>  <span class="va">...</span></span>
<span><span class="op">)</span></span>
<span></span>
<span><span class="fu">dst01_3_lyt</span><span class="op">(</span></span>
<span>  <span class="va">arm_var</span>,</span>
<span>  <span class="va">status_treatment_var</span>,</span>
<span>  <span class="va">completed_trt_lbl</span>,</span>
<span>  <span class="va">discontinued_trt_lbl</span>,</span>
<span>  <span class="va">ongoing_trt_lbl</span>,</span>
<span>  <span class="va">lbl_overall</span>,</span>
<span>  <span class="va">deco</span>,</span>
<span>  <span class="va">...</span></span>
<span><span class="op">)</span></span>
<span></span>
<span><span class="fu">dst01_3_pre</span><span class="op">(</span></span>
<span>  <span class="va">adam_db</span>,</span>
<span>  status_var <span class="op">=</span> <span class="st">"EOSSTT"</span>,</span>
<span>  disc_reason_var <span class="op">=</span> <span class="st">"DCSREAS"</span>,</span>
<span>  status_treatment_var <span class="op">=</span> <span class="st">"EOTSTT"</span>,</span>
<span>  <span class="va">...</span></span>
<span><span class="op">)</span></span>
<span></span>
<span><span class="fu">dst01_3_post</span><span class="op">(</span><span class="va">tlg</span>, prune_0 <span class="op">=</span> <span class="cn">TRUE</span>, deco <span class="op">=</span> <span class="fu"><a href="std_deco.html">std_deco</a></span><span class="op">(</span><span class="st">"DST01"</span><span class="op">)</span>, <span class="va">...</span><span class="op">)</span></span>
<span></span>
<span><span class="va">dst01_3</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="format">Format<a class="anchor" aria-label="anchor" href="#format"></a></h2>
    <p>An object of class <code>chevron_t</code> of length 1.</p>
    </div>
    <div class="section level2">
    <h2 id="arguments">Arguments<a class="anchor" aria-label="anchor" href="#arguments"></a></h2>
    <dl><dt>adam_db</dt>
<dd><p>(<code>dm</code>) object containing the <code>ADaM</code> datasets</p></dd>


<dt>arm_var</dt>
<dd><p>(<code>character</code>) variable used for column splitting</p></dd>


<dt>status_var</dt>
<dd><p>(<code>character</code>) variable used to define patient status. Default is <code>EOSSTT</code>, however can also be a
variable name with the pattern <code>EOPxxSTT</code> where <code>xx</code> must be substituted by 2 digits referring to the analysis
period.</p></dd>


<dt>disc_reason_var</dt>
<dd><p>(<code>character</code>) variable used to define reason for patient withdrawal. Default is <code>DCSREAS</code>,
however can also be a variable with the pattern <code>DCPxxRS</code> where <code>xx</code> must be substituted by 2 digits referring to
the analysis period.</p></dd>


<dt>status_treatment_var</dt>
<dd><p>(<code>string</code>) variable used to define the treatment status of the patients. Default is
<code>EOTSTT</code>, however can also be a variable with the pattern <code>EOTxxSTT</code> where <code>xx</code> must be substituted by 2 digits
referring to the analysis period.</p></dd>


<dt>lbl_overall</dt>
<dd><p>(<code>character</code>) label used for overall column, if set to <code>NULL</code> the overall column is omitted</p></dd>


<dt>deco</dt>
<dd><p>(<code>character</code>) decoration with <code>title</code>, <code>subtitles</code> and <code>main_footer</code> content</p></dd>


<dt>...</dt>
<dd><p>not used.</p></dd>


<dt>completed_trt_lbl</dt>
<dd><p>(<code>string</code>) associated with completed treatment and found in the columns given by
<code>status_treatment_var</code>. By Default <code>COMPLETED</code>.</p></dd>


<dt>discontinued_trt_lbl</dt>
<dd><p>(<code>string</code>) associated with discontinued treatment and found in the columns given by
<code>status_treatment_var</code>. By Default <code>DISCONTINUED</code>.</p></dd>


<dt>ongoing_trt_lbl</dt>
<dd><p>(<code>string</code>) associated with ongoing treatment and found in the columns given by
<code>status_treatment_var</code>. By Default `ONGOING.</p></dd>


<dt>tlg</dt>
<dd><p>(<code>TableTree</code>, <code>Listing</code> or <code>ggplot</code>) object typically produced by a <code>main</code> function.</p></dd>


<dt>prune_0</dt>
<dd><p>(<code>logical</code>) remove 0 count rows</p></dd>

</dl></div>
    <div class="section level2">
    <h2 id="details">Details<a class="anchor" aria-label="anchor" href="#details"></a></h2>
    
<ul><li><p>Non-standard disposition table summarizing the reasons for patient withdrawal and treatment status.</p></li>
<li><p>Withdrawal reasons are grouped into Safety and Non-Safety issues.</p></li>
<li><p>Safety issues include Death and Adverse Events.</p></li>
<li><p>Numbers represent absolute numbers of patients and fraction of <code>N</code>.</p></li>
<li><p>Remove zero-count rows.</p></li>
<li><p>Split columns by arm.</p></li>
<li><p>Include a total column by default.</p></li>
<li><p>Sort withdrawal reasons by alphabetic order.</p></li>
</ul></div>
    <div class="section level2">
    <h2 id="functions">Functions<a class="anchor" aria-label="anchor" href="#functions"></a></h2>
    
<ul><li><p><code>dst01_3_main()</code>: Main TLG function</p></li>
<li><p><code>dst01_3_lyt()</code>: Layout</p></li>
<li><p><code>dst01_3_pre()</code>: Preprocessing</p></li>
<li><p><code>dst01_3_post()</code>: Postprocessing</p></li>
</ul></div>
    <div class="section level2">
    <h2 id="note">Note<a class="anchor" aria-label="anchor" href="#note"></a></h2>
    
<ul><li><p><code>adam_db</code> object must contain an <code>adsl</code> table with the column specified in <code>status</code>, <code>status_treatment</code> and
<code>disc_reason_var</code>.</p></li>
</ul></div>

    <div class="section level2">
    <h2 id="ref-examples">Examples<a class="anchor" aria-label="anchor" href="#ref-examples"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://cynkra.github.io/dm/" class="external-link">dm</a></span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://magrittr.tidyverse.org" class="external-link">magrittr</a></span><span class="op">)</span></span></span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="va">db</span> <span class="op">&lt;-</span> <span class="va">syn_data</span> <span class="op"><a href="https://magrittr.tidyverse.org/reference/pipe.html" class="external-link">%&gt;%</a></span></span></span>
<span class="r-in"><span>  <span class="fu">dst01_3_pre</span><span class="op">(</span><span class="op">)</span></span></span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="fu">dst01_3_main</span><span class="op">(</span><span class="va">db</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [[1]]</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                          A: Drug X    B: Placebo   C: Combination   All Patients</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                           (N=134)      (N=134)        (N=132)         (N=400)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> ————————————————————————————————————————————————————————————————————————————————</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Completed Treatment      47 (35.1%)   35 (26.1%)     42 (31.8%)     124 (31.0%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Ongoing Treatment        39 (29.1%)   46 (34.3%)     46 (34.8%)     131 (32.8%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Discontinued Treatment   48 (35.8%)   53 (39.6%)     44 (33.3%)     145 (36.2%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [[2]]</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                   A: Drug X    B: Placebo   C: Combination   All Patients</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                    (N=134)      (N=134)        (N=132)         (N=400)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> —————————————————————————————————————————————————————————————————————————</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Completed Study   68 (50.7%)   66 (49.3%)     73 (55.3%)     207 (51.7%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [[3]]</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                     A: Drug X    B: Placebo   C: Combination   All Patients</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                      (N=134)      (N=134)        (N=132)         (N=400)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> ———————————————————————————————————————————————————————————————————————————————————————————</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Ongoing                             24 (17.9%)   28 (20.9%)     21 (15.9%)      73 (18.2%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Discontinued Study                  42 (31.3%)   40 (29.9%)     38 (28.8%)     120 (30.0%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Safety                            28 (20.9%)   29 (21.6%)     27 (20.5%)      84 (21.0%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     ADVERSE EVENT                    3 (2.2%)     6 (4.5%)       5 (3.8%)       14 (3.5%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     DEATH                           25 (18.7%)   23 (17.2%)     22 (16.7%)      70 (17.5%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     LACK OF EFFICACY                    0            0              0               0      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     PHYSICIAN DECISION                  0            0              0               0      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     PROTOCOL VIOLATION                  0            0              0               0      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     WITHDRAWAL BY PARENT/GUARDIAN       0            0              0               0      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     WITHDRAWAL BY SUBJECT               0            0              0               0      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Non-Safety                        14 (10.4%)   11 (8.2%)      11 (8.3%)       36 (9.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     ADVERSE EVENT                       0            0              0               0      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     DEATH                               0            0              0               0      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     LACK OF EFFICACY                 2 (1.5%)     2 (1.5%)       3 (2.3%)        7 (1.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     PHYSICIAN DECISION               2 (1.5%)     3 (2.2%)       2 (1.5%)        7 (1.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     PROTOCOL VIOLATION               5 (3.7%)     3 (2.2%)       4 (3.0%)       12 (3.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     WITHDRAWAL BY PARENT/GUARDIAN    4 (3.0%)     2 (1.5%)       1 (0.8%)        7 (1.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     WITHDRAWAL BY SUBJECT            1 (0.7%)     1 (0.7%)       1 (0.8%)        3 (0.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-in"><span><span class="fu">dst01_3_main</span><span class="op">(</span><span class="va">db</span>, lbl_overall <span class="op">=</span> <span class="cn">NULL</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [[1]]</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                          A: Drug X    B: Placebo   C: Combination</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                           (N=134)      (N=134)        (N=132)    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> —————————————————————————————————————————————————————————————————</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Completed Treatment      47 (35.1%)   35 (26.1%)     42 (31.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Ongoing Treatment        39 (29.1%)   46 (34.3%)     46 (34.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Discontinued Treatment   48 (35.8%)   53 (39.6%)     44 (33.3%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [[2]]</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                   A: Drug X    B: Placebo   C: Combination</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                    (N=134)      (N=134)        (N=132)    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> ——————————————————————————————————————————————————————————</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Completed Study   68 (50.7%)   66 (49.3%)     73 (55.3%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [[3]]</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                     A: Drug X    B: Placebo   C: Combination</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                      (N=134)      (N=134)        (N=132)    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> ————————————————————————————————————————————————————————————————————————————</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Ongoing                             24 (17.9%)   28 (20.9%)     21 (15.9%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Discontinued Study                  42 (31.3%)   40 (29.9%)     38 (28.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Safety                            28 (20.9%)   29 (21.6%)     27 (20.5%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     ADVERSE EVENT                    3 (2.2%)     6 (4.5%)       5 (3.8%)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     DEATH                           25 (18.7%)   23 (17.2%)     22 (16.7%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     LACK OF EFFICACY                    0            0              0       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     PHYSICIAN DECISION                  0            0              0       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     PROTOCOL VIOLATION                  0            0              0       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     WITHDRAWAL BY PARENT/GUARDIAN       0            0              0       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     WITHDRAWAL BY SUBJECT               0            0              0       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Non-Safety                        14 (10.4%)   11 (8.2%)      11 (8.3%)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     ADVERSE EVENT                       0            0              0       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     DEATH                               0            0              0       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     LACK OF EFFICACY                 2 (1.5%)     2 (1.5%)       3 (2.3%)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     PHYSICIAN DECISION               2 (1.5%)     3 (2.2%)       2 (1.5%)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     PROTOCOL VIOLATION               5 (3.7%)     3 (2.2%)       4 (3.0%)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     WITHDRAWAL BY PARENT/GUARDIAN    4 (3.0%)     2 (1.5%)       1 (0.8%)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     WITHDRAWAL BY SUBJECT            1 (0.7%)     1 (0.7%)       1 (0.8%)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-in"><span><span class="fu"><a href="run.html">run</a></span><span class="op">(</span><span class="va">dst01_3</span>, <span class="va">syn_data</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                       A: Drug X    B: Placebo   C: Combination   All Patients</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                        (N=134)      (N=134)        (N=132)         (N=400)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   ———————————————————————————————————————————————————————————————————————————————————————————</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Completed Study                     68 (50.7%)   66 (49.3%)     73 (55.3%)     207 (51.7%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Ongoing                             24 (17.9%)   28 (20.9%)     21 (15.9%)      73 (18.2%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Discontinued Study                  42 (31.3%)   40 (29.9%)     38 (28.8%)     120 (30.0%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     Safety                            28 (20.9%)   29 (21.6%)     27 (20.5%)      84 (21.0%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>       ADVERSE EVENT                    3 (2.2%)     6 (4.5%)       5 (3.8%)       14 (3.5%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>       DEATH                           25 (18.7%)   23 (17.2%)     22 (16.7%)      70 (17.5%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     Non-Safety                        14 (10.4%)   11 (8.2%)      11 (8.3%)       36 (9.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>       LACK OF EFFICACY                 2 (1.5%)     2 (1.5%)       3 (2.3%)        7 (1.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>       PHYSICIAN DECISION               2 (1.5%)     3 (2.2%)       2 (1.5%)        7 (1.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>       PROTOCOL VIOLATION               5 (3.7%)     3 (2.2%)       4 (3.0%)       12 (3.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>       WITHDRAWAL BY PARENT/GUARDIAN    4 (3.0%)     2 (1.5%)       1 (0.8%)        7 (1.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>       WITHDRAWAL BY SUBJECT            1 (0.7%)     1 (0.7%)       1 (0.8%)        3 (0.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Completed Treatment                 47 (35.1%)   35 (26.1%)     42 (31.8%)     124 (31.0%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Ongoing Treatment                   39 (29.1%)   46 (34.3%)     46 (34.8%)     131 (32.8%) </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Discontinued Treatment              48 (35.8%)   53 (39.6%)     44 (33.3%)     145 (36.2%) </span>
</code></pre></div>
    </div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="nest">
  <p>chevron is a part of the <strong>NEST</strong> and <a href="https://pharmaverse.org/" class="external-link"><strong>pharmaverse</strong></a>.</p>
</div>
<script type="text/javascript" src="../analytics.js"></script></footer></div>

  

  

  </body></html>

